查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2134993

全球叢集性頭痛流行病學分析與預測 - 2026 年

Global Cluster Headache Epidemiology Analysis and Forecast, 2026
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 132 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計到 2026 年，全球叢集性頭痛的患病人數將達到 942 萬，到 2035 年將達到 1,153 萬，年複合成長率為 2.3%。

隨著醫療專業人員、製藥公司、研究機構和政策制定者尋求全面了解疾病的盛行率、發病率、人口分佈、診斷率、疾病負擔和長期流行病學趨勢，全球叢集性頭痛流行病學分析市場的重要性日益凸顯。流行病學分析能夠準確估算患者群體，並識別不同地區尚未滿足的需求，為藥物研發、臨床試驗規劃、醫療資源分配和商業性預測奠定基礎。隨著人們對叢集性頭痛的認知不斷提高，新的治療方案不斷湧現，流行病學資訊在支持醫療決策方面發揮越來越重要的策略作用。

叢集性頭痛是一種罕見但極具破壞性的原發性頭痛疾病，其特徵是反覆發作的劇烈單側頭痛，並伴隨自主神經症狀。雖然其發生率相對低於偏頭痛和其他頭痛疾病，但其極高的疼痛強度、頻繁發作、生活品質下降、工作效率降低以及醫療資源消耗增加，都會造成嚴重的臨床、心理和社會經濟負擔。近期流行病學研究表明，叢集性頭痛影響全球約0.1%的人口，其中大多數確診病例為陣發性叢集性頭痛。

醫療保健分析、電子健康記錄、疾病登記、人工智慧和真實世界數據（RWE）平台的進步正在提高流行病學研究的品質和準確性。這些技術使研究人員能夠更有效地評估盛行率、發病率、人口統計學特徵、疾病進展、治療模式、醫療資源利用和區域差異。流行病學見解正日益為藥物研發、衛生經濟學研究、保險報銷計畫和臨床試驗參與者招募提供支持。

神經科醫師和頭痛專家的認知不斷提高，診斷標準不斷完善，以及對神經系統疾病研究投入的增加，正導致全球確診病例數量上升。同時，為減少診斷延誤和加強醫生教育而持續進行的工作，預計將在整個預測期內加強流行病學監測。隨著醫療系統繼續優先應對罕見神經系統疾病，對叢集性頭痛進行全面流行病學分析的需求預計將穩定成長。

市場促進因素

對該疾病的認知提高

  • 神經科醫生、基層醫療醫生和頭痛專家的認知不斷提高，這提高了識別叢集性頭痛的準確性，並減少了診斷延誤。
  • 教育計畫的引入和最新臨床指南的實施，使得流行病學報告和患者識別更加準確。

擴展真實世界醫療保健數據

  • 電子健康記錄、疾病登記、保險索賠資料庫和數位健康平台正在促進流行病學研究。
  • 大規模醫療保健資料集能夠更準確地評估盛行率、發病率、醫療保健利用率和治療結果。

加大神經學研究的投資

  • 各國政府、學術機構、製藥公司和研究機構都在不斷增加對神經系統疾病研究的投入。
  • 這些投資有助於改善流行病學監測，並支持臨床開發和醫療保健規劃。

流行病學分析的進展

  • 人工智慧、預測分析和真實世界數據 (RWE) 技術正在提高患者識別和疾病預測的準確性。
  • 先進的分析工具正在加深我們對人口趨勢、疾病負擔和長期流行病學模式的理解。

對罕見疾病資訊的需求日益成長

  • 隨著製藥業對罕見神經系統疾病的興趣日益濃厚，對患者群體進行詳細分析的需求也日益成長。
  • 準確的流行病學數據是新興療法的市場預測、臨床試驗設計和商業化策略的基礎。

市場限制因素

未能診斷及誤診

  • 叢集性頭痛經常被誤診，因為它的症狀與偏頭痛、鼻竇疾病和其他頭痛疾病的症狀重疊。
  • 診斷延遲持續影響流行病學估計和患者識別的準確性。

缺乏流行病學數據

  • 由於叢集性頭痛是一種相對罕見的神經系統疾病，因此在某些地區，大規模、基於人群的研究仍然有限。
  • 現有數據不足可能會限制全面評估疾病流行情況和區域差異的能力。

診斷標準的差異

  • 診斷方法、報告系統、醫療保健基礎設施以及獲得專科醫生的機會等方面的差異，導致各國流行病學報告缺乏一致性。

目錄

第1章執行摘要

  • 報告摘要
    • 叢集性頭痛的定義
    • 流行病學評估範圍
    • 研究目標
    • 主要發現
  • 流行病學方面的主要發現
    • 全球疫情概況
    • 全球流行情形概述
    • 陣發性叢集性頭痛和慢性叢集性頭痛負擔的比較
    • 按性別分類的流行病學趨勢
    • 按年齡分類的疾病分佈
    • 主要流行病學趨勢與未來展望
  • 關鍵策略要點

第2章 疾病與流行病學分析

  • 疾病概述
    • 定義和診斷標準
    • 疾病分類的歷史與變化
    • 病理學
    • 神經生物學機制
    • 疾病負擔對生活品質的影響
  • 病因和危險因子
    • 遺傳因素
    • 環境因素
    • 吸煙與生活方式的關係
    • 合併症
  • 疾病分類
    • 陣發性叢集性頭痛
    • 慢性叢集性頭痛
    • 原發性叢集性頭痛和續發性叢集性頭痛
  • 目前診斷狀態
    • 基於國際頭痛疾病分類的診斷標準
    • 鑑別診斷
    • 診斷影像和臨床檢測
    • 診斷方面的挑戰和延誤
  • 全球流行病學分析
    • 全球發病率
    • 全球盛行率
    • 已確診患病率
    • 接受治療的患者人數
    • 按年齡層別分類的流行病學
    • 性別流行病學
    • 疾病特異性流行病學
      • 陣發性叢集性頭痛
      • 慢性叢集性頭痛
  • 流行病學預測

第3章 市場動態

  • 市場促進因素
    • 對疾病的認知提高
    • 診斷率的提高
    • 擴大標靶治療的可及性
    • 神經控制技術的進步
  • 市場限制因素
    • 未能診斷及誤診
    • 治療選擇有限
    • 高昂的醫療費用
    • 與還款相關的問題
  • 市場機遇
    • 針對CGRP的療法
    • 神經控制裝置
    • 個人化醫療方法
    • 進入新興市場
  • 波特五力分析
  • PESTLE分析

第4章 商業和市場進入

  • 目前獲得治療的狀況
  • 定價分析
  • 贖回環境
  • 醫療保健支出趨勢
  • 患者支持和援助計劃

第5章：創新與通路的現狀

  • 創新趨勢
  • 新興藥物類別
    • CGRP單株抗體
    • 低分子量CGRP拮抗劑
    • 調變器
    • 生物製藥和新型靶點
  • 管線分析：依開發階段分類
    • 臨床前階段
    • 第一階段
    • 第二階段
    • 第三階段
  • 管道分析：按作用機制分析
  • 管道分析：按模式
    • 低分子化合物
    • 單株抗體
    • 醫療器材
    • 聯合治療
  • 臨床試驗現狀
    • 臨床試驗進行中
    • 已完成的臨床試驗
    • 臨床試驗的成功率
    • 關鍵試驗終點

第6章 當前治療狀況

  • 目前治療流程
  • 急性治療
    • 氧氣療法
    • 曲坦類藥物
      • Sumatriptan
      • 佐米曲坦
    • 鼻內療法
  • 預防性治療
    • 鈣離子通道阻斷劑
    • 皮質類固醇
    • 鋰
    • CGRP抑制劑
      • 加爾卡內茲馬
  • 神經調控療法及使用醫療設備的治療方法
    • 非侵入性迷走神經刺激療法
    • 新型神經調控技術
  • 未滿足的需求

第7章：全球叢集性頭痛流行病學報告：市場規模及預測

  • 全球市場規模分析
  • 全球市場預測
  • 市場預測：按治療類型分類
  • 市場預測：依給藥途徑分類
  • 市場預測：按分銷管道分類

第8章：全球聚集性頭痛流行病學報告的細分

  • 治療類型
    • 急性治療
    • 預防性治療
    • 橋接治療
  • 藥物類別
    • 曲坦類藥物
    • CGRP抑制劑
    • 鈣離子通道阻斷劑
    • 皮質類固醇
    • 其他
  • 依疾病類型
    • 陣發性叢集性頭痛
    • 慢性叢集性頭痛
  • 透過行政途徑
    • 注射藥物
    • 口服
    • 鼻內
  • 最終用戶
    • 醫院
    • 專科診所
    • 居家照護環境
    • 其他
  • 透過分銷管道
    • 醫院藥房
    • 零售藥房
    • 網路藥房

第9章 區域分析

  • 北美洲
    • 流行病學概述
    • 市場規模和成長率
    • 需求推動要素
    • 法規概述
    • 競爭強度
  • 歐洲
    • 流行病學概述
    • 市場規模和成長
    • 需求促進因素
    • 法規概述
    • 競爭強度
  • 亞太地區
    • 流行病學概述
    • 市場規模和成長
    • 需求促進因素
    • 法規概述
    • 競爭強度
  • 拉丁美洲
    • 流行病學概述
    • 市場規模和成長
    • 需求促進因素
    • 法規概述
    • 競爭強度
  • 中東和非洲
    • 流行病學概述
    • 市場規模和成長
    • 需求促進因素
    • 法規概述
    • 競爭強度

第10章 主要國家分析

  • 加拿大
  • 德國
  • 中國
  • 日本
  • 印度

第11章 法規與政策概述

  • 法規概述
  • 美國FDA框架
  • 歐洲藥品管理局 (EMA) 框架
  • 日本的PMDA框架
  • 印度的CDSCO框架
  • 中國國家藥品監督管理局 (NMPA) 框架
  • 孤兒藥和罕見疾病相關政策
  • 臨床試驗相關規定

第12章 競爭格局

  • 市佔率分析
  • 競爭基準
  • 已通過核准產品概覽
  • 管道競爭力
  • 策略聯盟
  • 授權和夥伴關係趨勢
  • 併購

第13章：公司簡介

  • Eli Lilly and Company
  • electroCore, Inc.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Medtronic plc
  • Grunenthal GmbH
  • Zosano Pharma Corp.
  • Bausch Health Companies Inc.
  • Viatris Inc.
  • Autonomic Technologies Inc.

第14章：未來展望

  • 流行病學的未來趨勢
  • 新的治療方案
  • 創新展望
  • 競爭演化
  • 預測期內的市場成長狀況

第15章：調查方法

  • 調查方法
  • 二手調查資料
  • 初步調查
  • 流行病學建模框架
  • 市場規模估算調查方法
  • 先決條件
  • 數據檢驗
  • 研究的局限性
簡介目錄
Product Code: KSI-008899

The Global Cluster Headache prevelance is expected to grow from 9.42 million patients in 2026 at a 2.3% CAGR to a market value of 11.53 million patients in 2035.

The global cluster headache epidemiology analysis market is becoming increasingly important as healthcare providers, pharmaceutical companies, research organizations, and policymakers seek comprehensive insights into disease prevalence, incidence, demographic distribution, diagnosis rates, disease burden, and long-term epidemiological trends. Epidemiological analysis serves as the foundation for drug development, clinical trial planning, healthcare resource allocation, and commercial forecasting by providing accurate estimates of patient populations and identifying unmet medical needs across different regions. As awareness of cluster headache improves and new therapeutic options emerge, epidemiological intelligence is playing an increasingly strategic role in supporting healthcare decision-making.

Cluster headache is a rare but highly debilitating primary headache disorder characterized by recurrent episodes of severe unilateral pain accompanied by autonomic symptoms. Although its prevalence is relatively low compared with migraine and other headache disorders, the condition imposes a substantial clinical, psychological, and socioeconomic burden due to its extreme pain intensity, frequent attacks, impaired quality of life, reduced work productivity, and increased healthcare utilization. Recent epidemiological research indicates that cluster headache affects approximately 0.1% of the global population, with episodic cluster headache representing the majority of diagnosed cases.

Advances in healthcare analytics, electronic health records, disease registries, artificial intelligence, and real-world evidence platforms are improving the quality and accuracy of epidemiological studies. These technologies enable researchers to evaluate prevalence, incidence, demographic characteristics, disease progression, treatment patterns, healthcare utilization, and regional variations more effectively. Epidemiological intelligence is increasingly supporting pharmaceutical pipeline development, health economics studies, reimbursement planning, and clinical trial recruitment.

Growing awareness among neurologists and headache specialists, improvements in diagnostic criteria, and increasing investment in neurological disorder research are expanding the diagnosed patient population worldwide. At the same time, ongoing efforts to reduce diagnostic delays and improve physician education are expected to strengthen epidemiological surveillance throughout the forecast period. As healthcare systems continue to prioritize rare neurological disorders, demand for comprehensive cluster headache epidemiology analysis is expected to increase steadily.

Market Drivers

Increasing Disease Awareness

  • Growing awareness among neurologists, primary care physicians, and headache specialists is improving recognition of cluster headache and reducing diagnostic delays.
  • Educational initiatives and updated clinical guidelines are contributing to more accurate epidemiological reporting and patient identification.

Expansion of Real-World Healthcare Data

  • Electronic health records, disease registries, insurance claims databases, and digital health platforms are strengthening epidemiological research.
  • Large healthcare datasets enable more accurate assessment of prevalence, incidence, healthcare utilization, and treatment outcomes.

Growing Investment in Neurology Research

  • Governments, academic institutions, pharmaceutical companies, and research organizations continue increasing investment in neurological disease research.
  • These investments improve epidemiological surveillance while supporting clinical development and healthcare planning.

Advances in Epidemiological Analytics

  • Artificial intelligence, predictive analytics, and real-world evidence technologies are improving patient identification and disease forecasting.
  • Advanced analytical tools enhance understanding of demographic trends, disease burden, and long-term epidemiological patterns.

Rising Demand for Rare Disease Intelligence

  • Increasing pharmaceutical interest in orphan neurological disorders has expanded the need for detailed patient population analysis.
  • Accurate epidemiological data supports market forecasting, clinical trial design, and commercialization strategies for emerging therapies.

Market Restraints

Underdiagnosis and Misdiagnosis

  • Cluster headache is frequently misdiagnosed because of symptom overlap with migraine, sinus disorders, and other headache conditions.
  • Delayed diagnosis continues to affect the accuracy of epidemiological estimates and patient identification.

Limited Epidemiological Data

  • Because cluster headache is a relatively rare neurological disorder, large-scale population studies remain limited in several regions.
  • Insufficient data availability may restrict comprehensive assessment of disease prevalence and regional variation.

Variability in Diagnostic Criteria

  • Differences in diagnostic practices, reporting systems, healthcare infrastructure, and access to specialists create inconsistencies in epidemiological reporting across countries.

Technology and Segment Insights

By Disease Type

  • Episodic cluster headache represents the largest patient segment because it accounts for the majority of diagnosed cases worldwide.
  • Chronic cluster headache represents a smaller but clinically significant population with greater disease burden, higher healthcare utilization, and increased treatment requirements.

By Age Group

  • Adults account for the largest patient population because cluster headache most commonly develops between early adulthood and middle age.
  • Although less common, pediatric and elderly cases continue to receive greater clinical attention as diagnostic awareness improves.

By Gender

  • Male patients continue to represent the majority of diagnosed cluster headache cases, although recent studies suggest the historical gender gap is gradually narrowing due to improved recognition among female patients.

By End User

  • Pharmaceutical companies remain the largest users of epidemiological analysis for patient segmentation, commercial forecasting, and clinical trial planning.
  • Healthcare providers utilize epidemiological data to optimize diagnosis, treatment planning, and healthcare resource allocation.
  • Academic institutions, government agencies, contract research organizations, and healthcare consulting firms also rely extensively on epidemiological intelligence to support research and healthcare policy development.

Regional Insights

  • North America dominates the global cluster headache epidemiology analysis market due to advanced healthcare infrastructure, comprehensive electronic health record systems, established neurological research programs, and high diagnostic awareness. The United States continues to lead epidemiological surveillance through extensive clinical research and real-world healthcare databases.
  • Europe represents another major market supported by strong academic collaboration, national disease registries, specialized headache centers, and comprehensive healthcare systems. Countries including Germany, the United Kingdom, France, Italy, Spain, and the Nordic nations continue to contribute significantly to epidemiological research.
  • Asia Pacific is expected to witness the fastest growth during the forecast period owing to expanding healthcare infrastructure, increasing neurological research, improving physician awareness, and greater investment in rare disease diagnosis across China, Japan, India, South Korea, and Australia.
  • Latin America and the Middle East & Africa are gradually strengthening epidemiological surveillance through healthcare modernization, expanding specialist services, and increased participation in multinational neurological research programs.

Competitive and Strategic Outlook

  • The global cluster headache epidemiology analysis market includes epidemiology research organizations, healthcare analytics companies, pharmaceutical consulting firms, contract research organizations, and real-world evidence providers. Competition increasingly focuses on delivering accurate prevalence estimates, demographic segmentation, disease burden analysis, healthcare utilization studies, and predictive epidemiological models that support pharmaceutical development and healthcare planning.
  • Organizations continue investing in artificial intelligence, predictive analytics, electronic health record integration, and longitudinal patient databases to improve epidemiological accuracy. Strategic collaborations among pharmaceutical companies, academic institutions, healthcare providers, and public health agencies continue to strengthen data quality and analytical capabilities while supporting development of innovative therapies for cluster headache.
  • Future market development is expected to emphasize precision epidemiology, digital health integration, real-world evidence generation, and advanced forecasting models capable of supporting personalized medicine, healthcare policy, and commercial decision-making.

Conclusion

The global cluster headache epidemiology analysis market is expected to experience steady growth as disease awareness, diagnostic accuracy, and neurological research continue to improve worldwide. Increasing investment in rare neurological disorders, expanding healthcare databases, advances in epidemiological analytics, and growing pharmaceutical interest in innovative therapies are expected to support sustained demand for comprehensive patient population intelligence. Although challenges related to underdiagnosis, limited epidemiological data, and regional variability remain, continued advances in healthcare analytics and real-world evidence will strengthen understanding of cluster headache disease burden and support strategic decision-making across healthcare and pharmaceutical industries.

Key Benefits of this Report

  • Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
  • Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
  • Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
  • Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
  • Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

  • Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

  • Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
  • Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
  • Competitive positioning, strategies, and market share evaluation, and trade analysis
  • Revenue growth and forecast assessment across segments and regions
  • Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

  • 1.1 Report Overview
    • 1.1.1 Definition of Cluster Headache
    • 1.1.2 Scope of Epidemiology Assessment
    • 1.1.3 Study Objectives
    • 1.1.4 Key Findings
  • 1.2 Key Epidemiology Insights
    • 1.2.1 Global Incidence Overview
    • 1.2.2 Global Prevalence Overview
    • 1.2.3 Episodic versus Chronic Cluster Headache Burden
    • 1.2.4 Gender-Based Epidemiology Trends
    • 1.2.5 Age-Specific Disease Distribution
    • 1.2.6 Major Epidemiological Trends and Future Outlook
  • 1.3 Key Strategic Takeaways

2. Disease & Epidemiology Analysis

  • 2.1 Disease Overview
    • 2.1.1 Definition and Diagnostic Criteria
    • 2.1.2 Disease History and Evolution of Classification
    • 2.1.3 Pathophysiology
    • 2.1.4 Neurobiological Mechanisms
    • 2.1.5 Disease Burden and Quality of Life Impact
  • 2.2 Etiology and Risk Factors
    • 2.2.1 Genetic Factors
    • 2.2.2 Environmental Factors
    • 2.2.3 Smoking and Lifestyle Associations
    • 2.2.4 Comorbidities
  • 2.3 Disease Classification
    • 2.3.1 Episodic Cluster Headache
    • 2.3.2 Chronic Cluster Headache
    • 2.3.3 Primary versus Secondary Cluster Headache
  • 2.4 Diagnostic Landscape
    • 2.4.1 Diagnostic Criteria Based on International Classification of Headache Disorders
    • 2.4.2 Differential Diagnosis
    • 2.4.3 Imaging and Laboratory Investigations
    • 2.4.4 Diagnostic Challenges and Delays
  • 2.5 Global Epidemiology Analysis
    • 2.5.1 Global Incidence
    • 2.5.2 Global Prevalence
    • 2.5.3 Diagnosed Prevalence
    • 2.5.4 Treated Population
    • 2.5.5 Epidemiology by Age Group
    • 2.5.6 Epidemiology by Gender
    • 2.5.7 Epidemiology by Disease Type
      • 2.5.7.1 Episodic Cluster Headache
      • 2.5.7.2 Chronic Cluster Headache
  • 2.6 Epidemiology Forecast

3. Market Dynamics

  • 3.1 Introduction
  • 3.2 Market Drivers
    • 3.2.1 Rising Disease Awareness
    • 3.2.2 Increasing Diagnosis Rates
    • 3.2.3 Growing Availability of Targeted Therapies
    • 3.2.4 Advancements in Neuromodulation Technologies
  • 3.3 Market Restraints
    • 3.3.1 Underdiagnosis and Misdiagnosis
    • 3.3.2 Limited Approved Therapies
    • 3.3.3 High Treatment Costs
    • 3.3.4 Reimbursement Challenges
  • 3.4 Market Opportunities
    • 3.4.1 CGRP-Targeted Therapies
    • 3.4.2 Neuromodulation Devices
    • 3.4.3 Personalized Medicine Approaches
    • 3.4.4 Emerging Markets Expansion
  • 3.5 Porter's Five Forces Analysis
  • 3.6 PESTLE Analysis

4. Commercial & Market Access

  • 4.1 Treatment Access Landscape
  • 4.2 Pricing Analysis
  • 4.3 Reimbursement Environment
  • 4.4 Healthcare Expenditure Trends
  • 4.5 Patient Assistance and Access Programs

5. Innovation & Pipeline Landscape

  • 5.1 Innovation Trends
  • 5.2 Emerging Drug Classes
    • 5.2.1 CGRP Monoclonal Antibodies
    • 5.2.2 Small Molecule CGRP Antagonists
    • 5.2.3 Neuromodulators
    • 5.2.4 Biologics and Novel Targets
  • 5.3 Pipeline Analysis by Development Stage
    • 5.3.1 Preclinical
    • 5.3.2 Phase I
    • 5.3.3 Phase II
    • 5.3.4 Phase III
  • 5.4 Pipeline Analysis by Mechanism of Action
  • 5.5 Pipeline Analysis by Modality
    • 5.5.1 Small Molecules
    • 5.5.2 Monoclonal Antibodies
    • 5.5.3 Medical Devices
    • 5.5.4 Combination Therapies
  • 5.6 Clinical Trial Landscape
    • 5.6.1 Ongoing Trials
    • 5.6.2 Completed Trials
    • 5.6.3 Trial Success Rates
    • 5.6.4 Key Trial Endpoints

6. Treatment Landscape

  • 6.1 Current Treatment Algorithm
  • 6.2 Acute Treatments
    • 6.2.1 Oxygen Therapy
    • 6.2.2 Triptans
      • 6.2.2.1 Sumatriptan
      • 6.2.2.2 Zolmitriptan
    • 6.2.3 Intranasal Therapies
  • 6.3 Preventive Treatments
    • 6.3.1 Calcium Channel Blockers
    • 6.3.2 Corticosteroids
    • 6.3.3 Lithium
    • 6.3.4 CGRP Inhibitors
      • 6.3.4.1 Galcanezumab
  • 6.4 Neuromodulation and Device-Based Therapies
    • 6.4.1 Non-invasive Vagus Nerve Stimulation
    • 6.4.2 Emerging Neuromodulation Technologies
  • 6.5 Unmet Needs

7. Global Cluster Headache Epidemiology Report Size & Forecast

  • 7.1 Global Market Size Analysis
  • 7.2 Global Market Forecast
  • 7.3 Market Forecast by Therapy Type
  • 7.4 Market Forecast by Route of Administration
  • 7.5 Market Forecast by Distribution Channel

8. Global Cluster Headache Epidemiology Report Segmentation

  • 8.1 By Treatment Type
    • 8.1.1 Acute Treatment
    • 8.1.2 Preventive Treatment
    • 8.1.3 Bridge Treatments
  • 8.2 By Drug Class
    • 8.2.1 Triptans
    • 8.2.2 CGRP Inhibitors
    • 8.2.3 Calcium Channel Blockers
    • 8.2.4 Corticosteroids
    • 8.2.5 Others
  • 8.3 By Disease Type
    • 8.3.1 Episodic Cluster Headache
    • 8.3.2 Chronic Cluster Headache
  • 8.4 By Route of Administration
    • 8.4.1 Injectable
    • 8.4.2 Oral
    • 8.4.3 Intranasal
  • 8.5 By End User
    • 8.5.1 Hospitals
    • 8.5.2 Specialty Clinics
    • 8.5.3 Homecare Settings
    • 8.5.4 Others
  • 8.6 By Distribution Channel
    • 8.6.1 Hospital Pharmacies
    • 8.6.2 Retail Pharmacies
    • 8.6.3 Online Pharmacies

9. Geographical Analysis

  • 9.1 North America
    • 9.1.1 Epidemiology Overview
    • 9.1.2 Market Size and Growth
    • 9.1.3 Demand Drivers
    • 9.1.4 Regulatory Overview
    • 9.1.5 Competitive Intensity
  • 9.2 Europe
    • 9.2.1 Epidemiology Overview
    • 9.2.2 Market Size and Growth
    • 9.2.3 Demand Drivers
    • 9.2.4 Regulatory Overview
    • 9.2.5 Competitive Intensity
  • 9.3 Asia-Pacific
    • 9.3.1 Epidemiology Overview
    • 9.3.2 Market Size and Growth
    • 9.3.3 Demand Drivers
    • 9.3.4 Regulatory Overview
    • 9.3.5 Competitive Intensity
  • 9.4 Latin America
    • 9.4.1 Epidemiology Overview
    • 9.4.2 Market Size and Growth
    • 9.4.3 Demand Drivers
    • 9.4.4 Regulatory Overview
    • 9.4.5 Competitive Intensity
  • 9.5 Middle East & Africa
    • 9.5.1 Epidemiology Overview
    • 9.5.2 Market Size and Growth
    • 9.5.3 Demand Drivers
    • 9.5.4 Regulatory Overview
    • 9.5.5 Competitive Intensity

10. Key Countries Analysis

  • 10.1 United States
  • 10.2 Canada
  • 10.3 Germany
  • 10.4 United Kingdom
  • 10.5 France
  • 10.6 Italy
  • 10.7 Spain
  • 10.8 China
  • 10.9 Japan
  • 10.10 India
  • 10.11 South Korea
  • 10.12 Australia
  • 10.13 Brazil
  • 10.14 Mexico
  • 10.15 Saudi Arabia
  • 10.16 South Africa

11. Regulatory & Policy Landscape

  • 11.1 Regulatory Overview
  • 11.2 United States FDA Framework
  • 11.3 European EMA Framework
  • 11.4 Japan PMDA Framework
  • 11.5 India CDSCO Framework
  • 11.6 China NMPA Framework
  • 11.7 Orphan Drug and Rare Disease Policies
  • 11.8 Clinical Trial Regulations

12. Competitive Landscape

  • 12.1 Market Share Analysis
  • 12.2 Competitive Benchmarking
  • 12.3 Approved Products Landscape
  • 12.4 Pipeline Competitiveness
  • 12.5 Strategic Collaborations
  • 12.6 Licensing and Partnership Trends
  • 12.7 Mergers and Acquisitions

13. Company Profiles

  • 13.1 Eli Lilly and Company
    • 13.1.1 Company Overview
    • 13.1.2 Approved Product: Emgality (galcanezumab)
    • 13.1.3 Key Indications
    • 13.1.4 Pipeline and Clinical Development
    • 13.1.5 Strategic Initiatives
  • 13.2 electroCore, Inc.
    • 13.2.1 Company Overview
    • 13.2.2 Approved Device: gammaCore
    • 13.2.3 Key Indications
    • 13.2.4 Pipeline and Innovation
    • 13.2.5 Strategic Initiatives
  • 13.3 Pfizer Inc.
    • 13.3.1 Company Overview
    • 13.3.2 Approved Product: Imitrex (sumatriptan)
    • 13.3.3 Key Indications
    • 13.3.4 Pipeline Portfolio
    • 13.3.5 Strategic Initiatives
  • 13.4 GlaxoSmithKline plc
    • 13.4.1 Company Overview
    • 13.4.2 Approved Product: Imigran (sumatriptan)
    • 13.4.3 Key Indications
    • 13.4.4 Pipeline Portfolio
    • 13.4.5 Strategic Initiatives
  • 13.5 Medtronic plc
    • 13.5.1 Company Overview
    • 13.5.2 Product
    • 13.5.3 Key Indications
    • 13.5.4 Pipeline Portfolio
    • 13.5.5 Strategic Initiatives
  • 13.6 Grunenthal GmbH
    • 13.6.1 Company Overview
    • 13.6.2 Approved Portfolio
    • 13.6.3 Key Indications
    • 13.6.4 Pipeline Portfolio
    • 13.6.5 Strategic Initiatives
  • 13.7 Zosano Pharma Corp.
    • 13.7.1 Company Overview
    • 13.7.2 Approved Product
    • 13.7.3 Key Indications
    • 13.7.4 Pipeline Portfolio
    • 13.7.5 Strategic Initiatives
  • 13.8 Bausch Health Companies Inc.
    • 13.8.1 Company Overview
    • 13.8.2 Approved Portfolio
    • 13.8.3 Key Indications
    • 13.8.4 Pipeline Portfolio
    • 13.8.5 Strategic Initiatives
  • 13.9 Viatris Inc.
    • 13.9.1 Company Overview
    • 13.9.2 Generic Sumatriptan Portfolio
    • 13.9.3 Key Indications
    • 13.9.4 Pipeline Portfolio
    • 13.9.5 Strategic Initiatives
  • 13.10 Autonomic Technologies Inc.
    • 13.10.1 Company Overview
    • 13.10.2 Product Portfolio
    • 13.10.3 Key Indications
    • 13.10.4 Pipeline Portfolio
    • 13.10.5 Strategic Initiatives

14. Future Outlook

  • 14.1 Future Epidemiology Trends
  • 14.2 Emerging Therapeutic Opportunities
  • 14.3 Innovation Outlook
  • 14.4 Competitive Evolution
  • 14.5 Market Growth Scenario Through Forecast Period

15. Methodology

  • 15.1 Research Methodology
  • 15.2 Secondary Research Sources
  • 15.3 Primary Research
  • 15.4 Epidemiology Modeling Framework
  • 15.5 Market Estimation Methodology
  • 15.6 Assumptions
  • 15.7 Data Validation
  • 15.8 Limitations